DE60220879D1 - Polymer-konjugate von neublastin und methoden für deren verwendung - Google Patents

Polymer-konjugate von neublastin und methoden für deren verwendung

Info

Publication number
DE60220879D1
DE60220879D1 DE60220879T DE60220879T DE60220879D1 DE 60220879 D1 DE60220879 D1 DE 60220879D1 DE 60220879 T DE60220879 T DE 60220879T DE 60220879 T DE60220879 T DE 60220879T DE 60220879 D1 DE60220879 D1 DE 60220879D1
Authority
DE
Germany
Prior art keywords
neublastine
methods
polymer conjugates
conjugates
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220879T
Other languages
English (en)
Other versions
DE60220879T2 (de
Inventor
Dinah W Sah
R Blake Pepinsky
Paula Ann Borjack-Sjodin
Stephan S Miller
Anthony Rossomando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE60220879D1 publication Critical patent/DE60220879D1/de
Publication of DE60220879T2 publication Critical patent/DE60220879T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
DE60220879T 2001-02-01 2002-01-25 Polymer-konjugate von neublastin und methoden für deren verwendung Expired - Lifetime DE60220879T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
US266071P 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
DE60220879D1 true DE60220879D1 (de) 2007-08-09
DE60220879T2 DE60220879T2 (de) 2008-03-06

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220879T Expired - Lifetime DE60220879T2 (de) 2001-02-01 2002-01-25 Polymer-konjugate von neublastin und methoden für deren verwendung

Country Status (36)

Country Link
EP (2) EP1355936B1 (de)
JP (2) JP4259868B2 (de)
KR (2) KR100872807B1 (de)
CN (1) CN1500095B (de)
AR (1) AR035077A1 (de)
AT (1) ATE365748T1 (de)
AU (1) AU2002247037B2 (de)
BG (1) BG66393B1 (de)
BR (1) BR0206852A (de)
CA (1) CA2436407C (de)
CY (1) CY1106886T1 (de)
CZ (1) CZ20032080A3 (de)
DE (1) DE60220879T2 (de)
DK (1) DK1355936T3 (de)
EA (1) EA009771B1 (de)
EE (1) EE05537B1 (de)
ES (1) ES2289091T3 (de)
GE (1) GEP20063916B (de)
HK (1) HK1057759A1 (de)
HU (1) HU228973B1 (de)
IL (2) IL156941A0 (de)
IS (1) IS2867B (de)
MX (1) MXPA03006805A (de)
MY (1) MY143685A (de)
NO (1) NO332150B1 (de)
NZ (1) NZ527863A (de)
PL (1) PL211162B1 (de)
PT (1) PT1355936E (de)
RS (1) RS50857B (de)
SG (1) SG149685A1 (de)
SI (1) SI1355936T1 (de)
SK (1) SK288123B6 (de)
TR (1) TR200301208T2 (de)
UA (2) UA100967C2 (de)
WO (1) WO2002060929A2 (de)
ZA (1) ZA200305733B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
CA2473526C (en) * 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
SI2246362T1 (sl) * 2003-01-31 2014-04-30 Biogen Idec Ma Inc. Polimerni konjugati mutiranega neoblastina
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
EP1636260B1 (de) * 2003-06-10 2009-02-18 Nsgene A/S Verbesserte sezernierung von neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
EA013565B1 (ru) * 2004-08-19 2010-06-30 Байоджен Айдек Ма Инк. Варианты полипептидов нейбластина, способы их получения и их применение
US8722862B2 (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (de) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
MX2009002820A (es) 2006-09-15 2009-06-04 Creabilis Therapeutics Spa Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
PL3257564T5 (pl) * 2011-11-02 2024-10-07 F. Hoffmann-La Roche Ag Chromatografia elucyjna z przeładowaniem
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
JP2002531128A (ja) * 1998-12-09 2002-09-24 アムジエン・インコーポレーテツド 神経栄養因子ｇｒｎｆ４
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。

Also Published As

Publication number Publication date
DK1355936T3 (da) 2007-10-29
BG66393B1 (bg) 2013-11-29
JP2005503763A (ja) 2005-02-10
CN1500095B (zh) 2010-06-16
SI1355936T1 (sl) 2007-12-31
GEP20063916B (en) 2006-09-11
EA009771B1 (ru) 2008-04-28
CA2436407C (en) 2011-08-30
NO20033441L (no) 2003-10-01
EP1355936B1 (de) 2007-06-27
EP1355936A2 (de) 2003-10-29
AR035077A1 (es) 2004-04-14
NO20033441D0 (no) 2003-08-01
UA100967C2 (ru) 2013-02-25
NZ527863A (en) 2006-09-29
EA200300852A1 (ru) 2004-06-24
CA2436407A1 (en) 2002-08-08
ATE365748T1 (de) 2007-07-15
WO2002060929A3 (en) 2003-03-06
HU228973B1 (en) 2013-07-29
SG149685A1 (en) 2009-02-27
JP2009039135A (ja) 2009-02-26
BR0206852A (pt) 2005-05-03
IL156941A0 (en) 2004-02-08
NO332150B1 (no) 2012-07-09
WO2002060929A2 (en) 2002-08-08
AU2002247037B2 (en) 2007-08-16
ES2289091T3 (es) 2008-02-01
MXPA03006805A (es) 2003-11-13
IS6879A (is) 2003-07-17
KR100960063B1 (ko) 2010-05-31
RS50857B (sr) 2010-08-31
EE05537B1 (et) 2012-04-16
CN1500095A (zh) 2004-05-26
UA82983C2 (ru) 2008-06-10
KR20080098662A (ko) 2008-11-11
CZ20032080A3 (cs) 2003-10-15
HK1057759A1 (en) 2004-04-16
CY1106886T1 (el) 2012-09-26
DE60220879T2 (de) 2008-03-06
SK288123B6 (sk) 2013-09-03
SK9712003A3 (en) 2004-01-08
ZA200305733B (en) 2005-02-23
EP1862475A1 (de) 2007-12-05
HUP0500637A2 (hu) 2005-09-28
PL211162B1 (pl) 2012-04-30
EE200300355A (et) 2003-10-15
KR20030074766A (ko) 2003-09-19
MY143685A (en) 2011-06-30
KR100872807B1 (ko) 2008-12-09
PL372101A1 (en) 2005-07-11
JP4423338B2 (ja) 2010-03-03
IS2867B (is) 2014-02-15
PT1355936E (pt) 2007-09-28
YU61003A (sh) 2006-05-25
TR200301208T2 (tr) 2005-05-23
BG108111A (bg) 2004-12-30
JP4259868B2 (ja) 2009-04-30
HUP0500637A3 (en) 2010-01-28
IL156941A (en) 2008-11-03

Similar Documents

Publication Publication Date Title
DE60220879D1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
ATE271066T1 (de) Lösliche mutante ctla4 moleküle und deren verwendung
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
DE50209372D1 (de) Konjugierte polymere enthaltend spirobifluoren-einheiten und deren verwendung
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
DE50200971D1 (de) Konjugierte polymere enthaltend spirobifluoren-einheiten und fluoren-einheiten und deren verwendung
DE60218695D1 (de) Biosensoren und messverfahren
NO20034114L (no) Superslukkebaserte biologiske analyser med flourescerende polymer
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60233192D1 (de) Hydrophobe und lipophobe zusammensetzung
FR2843963B1 (fr) Nouvelles molecules derivees de la noraporphine
DE60229770D1 (de) Reibungsreduzierende zusammensetzung und verfahren
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60229819D1 (de) Antriebsstrang und dessen Zusammenbaumethode
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE381329T1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE60211106D1 (de) Zusammensetzung zur Oxidationsfärbung von Keratinfasern
DE60041418D1 (de) Zusammensetzung für hydrogele, hydrogel und dessen verwendung
DE60201244D1 (de) Polymermodifizierte Gipsmembran und deren Verwendung
DE50011452D1 (de) Polyalkenalkohol-polyalkoxylate und deren verwendung in kraft- und schmierstoffen
FI20000292A0 (fi) Testausjärjestely ja testausmenetelmä
ATE281418T1 (de) Schlichtezusammensetzung, beschlichtete glasfasern sowie deren verwendung
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition